Oligonucleotide drugs are short, synthetic stretches of nucleic acid designed to silence, correct, or modulate specific genes inside living cells. Over the past decade they have moved from a niche curiosity to a genuine drug class, with more than a dozen approved therapies on the market and hundreds more in clinical trials. The field’s progress has hinged on solving two stubborn problems: keeping these fragile molecules intact long enough to reach their targets, and getting them inside the right cells once they arrive. Both problems are now yielding to a combination of clever chemistry and creative delivery systems, though significant hurdles remain.
How Oligonucleotide Drugs Work
Most conventional drugs are small molecules or proteins that block or activate a protein after it has already been made. Oligonucleotide drugs intervene earlier, at the level of RNA, the intermediate messenger that carries genetic instructions from DNA to the protein-making machinery. By binding to a target RNA sequence with high specificity, these drugs can shut down production of a disease-causing protein before it ever forms, or correct a faulty RNA message so the cell produces a functional protein instead of a broken one.
The main categories work through distinct mechanisms. Antisense oligonucleotides (ASOs) are single-stranded DNA-like molecules that bind to messenger RNA. Some trigger an enzyme called RNase H to chop up the RNA they latch onto. Others physically block the cellular machinery from reading the RNA or redirect the way the cell splices RNA segments together, which can restore a functional protein from a defective gene.1Molecular Therapy. Guidelines for Antisense Oligonucleotide Design and Insight Into Splice-modulating Mechanisms Small interfering RNAs (siRNAs) are double-stranded molecules that harness the cell’s own RNA interference pathway, loading into a protein complex called RISC that then hunts down and destroys matching RNA sequences.2PubMed Central. The RNA-induced silencing complex: a versatile gene-silencing machine A third category, aptamers, folds into three-dimensional shapes that bind directly to proteins rather than RNA, functioning more like antibodies than gene silencers.3PubMed Central. Aptamers as Therapeutics
Chemical Modifications That Made These Drugs Possible
Unmodified nucleic acids survive only minutes in the bloodstream. Enzymes called nucleases chew them up almost immediately, and the kidneys clear the fragments before they can reach target tissues. The entire oligonucleotide drug field depended on finding chemical tweaks that could protect these molecules without destroying their ability to bind RNA.
The most widely used modification is the phosphorothioate (PS) backbone, where one oxygen atom in the molecule’s sugar-phosphate spine is replaced with sulfur. This swap dramatically slows nuclease digestion and helps the drug stick to blood proteins, which carries it through the circulation and into cells more effectively.4Journal of the American Chemical Society. Origins of the Increased Affinity of Phosphorothioate-Modified Therapeutic Nucleic Acids for Proteins Nearly every approved oligonucleotide drug uses PS linkages somewhere in its design.
Sugar modifications add another layer of protection and binding strength. Two of the most common are 2′-O-methyl RNA, which adds a small chemical group to the sugar ring, and locked nucleic acid (LNA), which locks the sugar into a rigid shape. LNA modifications are especially potent: each LNA substitution strengthens binding to a target RNA strand by roughly seven times more than a 2′-O-methyl substitution, on average.5PubMed. Interplay of LNA and 2′-O-methyl RNA in the structure and thermodynamics of RNA hybrid systems That extra grip means designers can make shorter oligonucleotides that still hit their targets with high affinity, reducing the amount of drug needed per dose.6PubMed Central. Rational Design of Short Locked Nucleic Acid-Modified 2′-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro
Researchers often combine these modifications strategically along the same molecule. A “mixmer” design alternating 2′-O-methyl and LNA units, for example, has shown powerful activity as an inhibitor of RNA editing, outperforming other backbone designs in head-to-head comparisons.7PubMed Central. Potent and selective inhibition of A-to-I RNA editing with 2′-O-methyl/locked nucleic acid-containing antisense oligoribonucleotides Yet these chemical modifications introduce their own trade-offs, including immune-system activation and kidney stress, which drug designers must carefully balance.
Delivering Drugs to the Liver and Beyond
Chemistry alone does not solve the delivery problem. Even a nuclease-resistant oligonucleotide injected into the bloodstream tends to accumulate in the liver and kidneys, with very little reaching other organs. For liver diseases, this natural tendency is actually useful. For diseases of the brain, muscles, or eyes, it is a serious obstacle.
The biggest delivery breakthrough of the past decade is a sugar molecule called N-acetylgalactosamine, or GalNAc. When attached to an oligonucleotide, GalNAc acts as an address label, binding specifically to a receptor on liver cells called the asialoglycoprotein receptor. This receptor grabs the drug and pulls it inside the cell. The result is a dramatic improvement in potency: in mouse studies, GalNAc-conjugated antisense oligonucleotides were roughly ten-fold more potent than the same sequences delivered without the sugar tag.8Nucleic Acids Research. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice GalNAc conjugation has become the standard approach for liver-targeted oligonucleotide drugs and underpins several approved therapies.9PubMed Central. Delivery of Oligonucleotides to the Liver with GalNAc: From Research to Registered Therapeutic Drug
Lipid nanoparticles (LNPs), the same technology behind the mRNA COVID-19 vaccines, serve as another delivery vehicle. LNPs wrap oligonucleotides inside a tiny fat droplet that fuses with cell membranes and releases its cargo inside. Research on LNP design has shown that the internal structure of these particles matters as much as their composition: particles engineered with certain geometric arrangements of their lipid components escape the cell’s recycling compartments more efficiently and deliver their RNA payload to the right place inside the cell.10PubMed Central. Lipid nanoparticle topology regulates endosomal escape and delivery of RNA to the cytoplasm
Cell-penetrating peptides (CPPs), short chains of amino acids that can cross cell membranes, represent yet another approach. CPPs can be chemically attached to an oligonucleotide or simply mixed with one to form a complex. Early work showed that peptide-oligonucleotide conjugates entered cells over a period of hours, reaching both the cytoplasm and the nucleus, and produced dose-dependent biological effects at their target site.11PubMed. Conjugates of antisense oligonucleotides with the Tat and antennapedia cell-penetrating peptides Arginine-rich CPP designs have demonstrated efficacy in mouse models of Duchenne muscular dystrophy, delivering splice-correcting oligonucleotides to muscle tissue without the need for additional agents to help them escape the cell’s internal compartments.12PubMed Central. Cell penetrating peptide conjugates of steric block oligonucleotides
The Endosomal Escape Bottleneck
One of the field’s most persistent frustrations is what happens after an oligonucleotide enters a cell. Cells take up material by wrapping it in tiny membrane-bound sacs called endosomes, which are essentially recycling and degradation compartments. The drug needs to break out of the endosome to reach the cytoplasm, where it can actually do its job. Most of it never does. The vast majority of delivered oligonucleotides end up trapped and eventually destroyed inside the cell, wasting the dose.
Despite years of research, scientists still disagree on exactly how endosomal escape works. Several models have been proposed, including the idea that LNPs cause the endosome to swell and burst, or that the lipid particles fuse directly with the endosomal membrane. A recent reanalysis of the existing data argues that escape likely occurs through a mechanism called vesicle budding and collapse, where small buds form on the endosomal membrane and then rupture, releasing the contents. The same analysis identified a second bottleneck: once free in the cytoplasm, the drug and its lipid carrier can form an insoluble clump that dissolves slowly, further delaying its activity.13PubMed Central. Endosomal Escape of Lipid Nanoparticles: A Perspective on the Literature Data The limited understanding here is a real constraint: without a clear mechanistic picture, optimizing LNP formulations remains largely trial-and-error.14PubMed Central. Endosomal escape: A bottleneck for LNP-mediated therapeutics
Reaching Muscle, Brain, and Eye
For diseases outside the liver, delivery requires more creative strategies. Antibody-oligonucleotide conjugates (AOCs) represent one of the most promising new platforms. By linking an oligonucleotide to an antibody that recognizes a receptor on a specific tissue, researchers can direct the drug to organs that would otherwise be unreachable. Conjugates targeting the transferrin receptor on muscle cells achieved greater than 80% knockdown of target genes in mouse muscle tissue, a level of silencing that would be nearly impossible with an unconjugated drug.15PubMed Central. Targeted tissue delivery of RNA therapeutics using antibody–oligonucleotide conjugates In another study, a conjugate targeting the same receptor family silenced gene expression in both heart and skeletal muscle for a full month after a single intravenous injection in mice, and in a disease model the treatment improved running performance.16PubMed. Development of antibody-siRNA conjugate targeted to cardiac and skeletal muscles
This approach has now reached human patients. A clinical trial of del-desiran, an antibody-oligonucleotide conjugate for myotonic dystrophy type 1, showed evidence of drug delivery to muscle and correction of the aberrant RNA splicing that characterizes the disease, though two serious adverse events were also reported.17PubMed. An Antibody-Oligonucleotide Conjugate for Myotonic Dystrophy Type 1
Reaching the brain requires a different approach entirely. The blood-brain barrier blocks most drugs from entering the central nervous system, so oligonucleotides targeting neurological diseases are typically injected directly into the spinal fluid, a route called intrathecal delivery. Imaging studies in rats have traced what happens next: the drug spreads upward along the spinal cord, coats the membranes surrounding the brain, and then gradually passes into brain tissue, first accumulating in support cells and then in neurons. In these studies, target protein levels in the brain dropped markedly within two weeks.18PubMed Central. Brain pharmacology of intrathecal antisense oligonucleotides revealed through multimodal imaging Pharmacokinetic modeling of this delivery route in primates has helped researchers optimize injection volume and duration for maximum brain coverage.19PubMed Central. A mechanistic pharmacokinetic model for intrathecal administration of antisense oligonucleotides
The eye is another organ well suited to oligonucleotide therapy. Its enclosed, fluid-filled structure means that an intravitreal injection (directly into the eye) delivers a high local concentration of drug while minimizing exposure to the rest of the body. Dozens of clinical trials are underway for inherited retinal diseases using this approach.20PubMed Central. Delivery of Antisense Oligonucleotides to the Mouse Retina
Clinical Milestones
The approved oligonucleotide drugs on the market today illustrate how far the field has come. In Duchenne muscular dystrophy (DMD), a devastating muscle-wasting disease caused by mutations in the dystrophin gene, four antisense oligonucleotides have received FDA approval: eteplirsen, golodirsen, viltolarsen, and casimersen.21PubMed Central. FDA-approved antisense oligonucleotide therapies for duchenne muscular dystrophy: current status and future outlook Each targets a different exon of the dystrophin gene, using a strategy called exon skipping to restore the reading frame of the mutated RNA so cells can produce a shortened but partially functional version of the protein. Eteplirsen, the first to be approved in 2016, works by skipping exon 51 and uses a morpholino backbone chemistry that is charge-neutral and nuclease-resistant.22PubMed Central. Eteplirsen in the treatment of Duchenne muscular dystrophy These approvals were granted under accelerated pathways based on modest increases in dystrophin protein rather than definitive functional improvement, which has generated ongoing debate about their clinical benefit.
In cardiovascular medicine, inclisiran has opened a new front. This siRNA drug silences the gene for PCSK9, a protein that prevents liver cells from clearing LDL cholesterol from the blood. Using GalNAc conjugation for liver-targeted delivery, inclisiran achieves sustained LDL-C lowering with just two or three injections per year, a dosing schedule that could dramatically improve adherence compared to the daily or biweekly regimens required by other cholesterol-lowering drugs.23PubMed Central. Inclisiran: a new generation of lipid-lowering siRNA therapeutic The twice-yearly maintenance dosing produces LDL-C reductions comparable to existing PCSK9 antibodies, making it especially attractive for high-risk patients who struggle with frequent dosing or cannot tolerate statins.24Cardiovascular Prevention and Pharmacotherapy. Next-generation PCSK9 inhibitors: clinical evidence and future directions for cardiovascular prevention
Perhaps the most striking proof of concept is the individualized use of oligonucleotides for ultra-rare diseases. Milasen, an ASO developed for a single patient with a form of Batten disease, demonstrated that the platform could be tailored to a unique mutation in one individual. The drug was designed, manufactured, and administered within roughly a year after identifying the patient’s specific genetic defect.25Elsevier / Molecular Therapy Nucleic Acids. Tailored antisense oligonucleotides for ultrarare CNS diseases: An experience-based best practice framework for individual patient evaluation This kind of bespoke medicine was essentially unthinkable with traditional drug classes.
Immune Activation and Kidney Concerns
Oligonucleotide drugs are not inert passengers in the body. The immune system has evolved pattern-recognition receptors specifically tuned to detect foreign nucleic acids, and some of the same chemical modifications that make oligonucleotides durable can also trigger these alarms. Phosphorothioate-modified ASOs, for instance, can activate an immune sensor called TLR9, leading to inflammatory responses. Research has found that this activation depends not just on the ASO’s sequence but also on how the drug interacts with extracellular proteins like HMGB1 and S100A8, which appear to chaperone the ASO to the receptor. Reducing the proportion of PS linkages in the backbone lowered immune activation, suggesting that the drug’s protein-binding properties are a key driver of the response.26Nucleic Acids Research. Insights into innate immune activation via PS-ASO–protein–TLR9 interactions
Some oligonucleotides are intentionally designed to activate the immune system rather than avoid it. In cancer immunotherapy, nucleic acids and oligonucleotides can stimulate innate immune cells, encode immunostimulatory proteins, or silence genes that act as brakes on the immune response.27PubMed Central. Nucleic acid and oligonucleotide delivery for activating innate immunity in cancer immunotherapy In these contexts, what would normally be considered a side effect becomes the therapeutic goal.
Kidney toxicity is another concern that comes up repeatedly in the oligonucleotide safety literature. Because the kidneys filter and concentrate these molecules from the blood, they accumulate high local drug concentrations. This is an important consideration during clinical development, and monitoring kidney function is standard practice for patients on ASO therapies.28PubMed Central. Nephrotoxicity of marketed antisense oligonucleotide drugs
Stereochemistry and the Precision Manufacturing Frontier
A subtlety that rarely gets public attention but has major implications for drug performance is stereochemistry. Each phosphorothioate linkage in an oligonucleotide can exist in two mirror-image forms, called Rp and Sp. Standard manufacturing produces a random mixture of both at every position, which means a 20-unit-long PS oligonucleotide is actually a cocktail of over a million distinct molecular variants. Most of these variants have slightly different properties in terms of stability, binding, and activity.
Researchers have developed methods to control which form appears at each position, creating what are called stereopure oligonucleotides. Studies in mice showed that placing the Rp form at the front end and the Sp form at the back end of an siRNA strand improved both how long the drug lasted in the body and how effectively it silenced its target gene.29Nucleic Acids Research. Chirality matters: stereo-defined phosphorothioate linkages at the termini of small interfering RNAs improve pharmacology in vivo Follow-up work combining stereopure PS linkages with a newer backbone modification called phosphoryl guanidine (PN) showed further gains in potency and duration of gene silencing in liver cells, outperforming the chemical formats used in currently approved drugs.30PubMed Central. Impact of stereopure chimeric backbone chemistries on the potency and durability of gene silencing by RNA interference If these improvements translate to the clinic, stereopure manufacturing could allow lower doses and less frequent injections.
Stability in the Vial
Stability is not just a problem inside the body. Keeping oligonucleotide drugs intact during manufacturing, storage, and shipping presents its own challenges. These molecules can degrade when exposed to heat, light, or oxidative conditions. Formulation studies on LNA-modified oligonucleotides found that heat treatment and gamma irradiation, a common sterilization method, caused substantial degradation.31PubMed. Development of stable liquid formulations for oligonucleotides This means conventional sterilization approaches used for many injectable drugs simply do not work for oligonucleotides, and manufacturers must rely on sterile filtration and cold-chain logistics instead. The practical result is higher manufacturing costs and more complex supply chains, especially for drugs destined for parts of the world where refrigeration infrastructure is limited.
The Push Toward Oral Delivery
Nearly all approved oligonucleotide drugs require injection, whether subcutaneously, intravenously, intrathecally, or into the eye. An oral pill would be transformative for patient convenience and adherence, especially for chronic conditions requiring lifelong treatment. But the gastrointestinal tract is a hostile environment for nucleic acids. Stomach acid, digestive enzymes, the mucus lining, and the intestinal cell barrier all conspire to destroy or block these molecules before they can reach the bloodstream.32PubMed. Oral delivery of nucleic acid therapeutics: Challenges, strategies, and opportunities
Researchers are exploring various nanoparticle-based strategies to protect oligonucleotides through the GI tract, including polymer-based particles, lipid nanoparticles, and naturally derived extracellular vesicles. Each approach attempts to shield the drug from degradation while promoting absorption through the intestinal wall.33PubMed Central. Oral Delivery of Nucleic Acid Therapies for Local and Systemic Action Progress has been slow compared to the rapid advances in injectable delivery, and no oral oligonucleotide has yet reached late-stage clinical trials. But given the enormous commercial and medical incentive, this is an area where substantial investment continues to flow, and early-stage results are being watched closely by pharmaceutical companies across the field.